Photodynamic Therapy Market_医药健康与生命科学_环球市场

Report Overview

The Global Photodynamic Therapy Market Size is expected to be worth around US$ 10.1 Billion by 2034, from US$ 4.8 Billion in 2024, growing at a CAGR of 7.6% during the forecast period from 2025 to 2034. North America held a dominant market position, capturing more than a 36.1% share and holds US$ 1.7 Billion market value for the year.

Photodynamic Therapy Market Size Analysis

Photodynamic Therapy Market, Global Analysis, 2020-2024 (US$ Billion)

Photodynamic Therapy Market, Product Type Analysis, 2020-2024 (US$ Billion)

Photodynamic Therapy Market, Regional Analysis, 2020-2024 (US$ Billion)

Region	2020	2021	2022	2023	2024
North America	0.87	0.89	1.16	1.62	1.74
Europe	0.77	0.78	1.01	1.41	1.50
Asia-Pacific	0.45	0.46	0.62	0.89	0.98

Key Regions and Countries

North America
- US
- Canada
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Russia
- Netherland
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- New Zealand
- Singapore
- Thailand
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Rest of MEA

Key Players Analysis

The Photodynamic Therapy (PDT) market is marked by a dynamic competitive landscape driven by technological innovation, regulatory frameworks, and the efforts of leading players striving for market dominance. PDT, a minimally invasive treatment using photosensitizing agents activated by light to target and destroy abnormal cells, has gained traction in fields like oncology, dermatology, and ophthalmology.

Key companies such as Biofrontera AG and Theralase Technologies Inc. are at the forefront, offering extensive PDT product portfolios. These players capitalize on strong R&D capabilities and strategic collaborations to develop advanced photosensitizers, light sources, and delivery systems, thereby improving treatment outcomes. Partnerships with healthcare institutions and research bodies support clinical trials and broaden market penetration, further solidifying their positions.

Mergers and acquisitions are also common, enabling companies to diversify offerings, expand geographic presence, and enhance technological expertise. Regulatory frameworks play a crucial role, ensuring product safety and efficacy, thereby building consumer trust and facilitating market growth. Cutting-edge advancements, including next-generation photosensitizers, targeted delivery mechanisms, and fluorescence imaging technologies, are shaping the market’s future and driving its expansion.

Recent Developments

In February 2023, Bausch + Lomb and Modulight, a biomedical laser company, received FDA approval for the ML6710i photodynamic laser. This approval allows its equivalent use with Bausch + Lomb’s VISUDYNE for photodynamic therapy (PDT) in treating predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration (AMD).
In June 2022, LUMIBIRD established a new subsidiary in Mumbai named Lumibird Medical India. The primary objective of this venture is to drive the sales of Quantel Medical and Ellex products in the Indian market. Lumibird Medical India will focus on offering a diverse array of ophthalmic lasers, ultrasound platforms and cutting-edge equipment designed for both diagnosis and treatment purposes. This expansion reflects LUMIBIRD’s commitment to strengthening its footprint in India and delivering advanced medical technologies to the healthcare sector in the region.
In March 2021, Boston Scientific unveiled a definitive agreement with Baring Private Equity Asia (BPEA) for the acquisition of the worldwide surgical business of Lumenis LTD. This segment of Lumenis specializes in advanced laser systems, fibers, and accessories utilized in urology and otolaryngology procedures.